Macropa-NCS |
Katalog-Nr.GC33335 |
Macropa-NCS ist sowohl mit Trastuzumab als auch mit dem prostataspezifischen Membranantigen-Targeting-Wirkstoff RPS-070 konjugiert. Ein vielversprechendes therapeutisches Radionuklid zur Behandlung von Weichteilmetastasen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2146095-31-8
Sample solution is provided at 25 µL, 10mM.
Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070. A promising therapeutic radionuclide applied in the treatment of soft-tissue metastases[1].
[1]. Thiele NA, et al. An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy. Angew Chem Int Ed Engl. 2017 Nov 13;56(46):14712-14717.
Average Rating: 5
(Based on Reviews and 4 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *